Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D CurranG Giaccone

Abstract

Identification of prognostic factors in patients with malignant pleural mesothelioma based on prospectively collected international data. From October 1984 to October 1993, 204 eligible adult patients with malignant pleural mesothelioma were entered into five consecutive prospective European Organization for Research and Treatment of Cancer (EORTC) phase II clinical trials designed to assess the efficacy of various anticancer drugs (mitoxantrone, epidoxorubicin, etoposide, and paclitaxel). The Cox model was used to assess 13 factors related to biology and disease history with respect to survival. The median survival duration was 12.6 months from diagnosis and 8.4 months from trial entry. In the multivariate analysis, poor prognosis was associated with a poor performance status, a high WBC count, a probable/possible histologic diagnosis of mesothelioma, male gender, and having sarcomatous tissue as the histologic subtype. Taking these five factors into consideration, patients were classified into two groups: a good-prognosis group (1-year survival rate, 40%; 95% confidence interval [CI], 30% to 50%) and a poor-prognosis group (1-year survival, 12%; 95% CI, 4% to 20%). These results may help to design new clinical trials in pleur...Continue Reading

Citations

Mar 31, 2000·Current Opinion in Pulmonary Medicine·A M Boylan
Mar 1, 2003·British Journal of Cancer·S TomekC Manegold
Apr 9, 2004·International Journal of Occupational and Environmental Health·Duncan J StewartKenneth J O'Byrne
Sep 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Walter WederRolf A Stahel
Mar 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giovanni L CeresoliArmando Santoro
Nov 3, 2006·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Hongqiang XiaTomoko Itazawa
Feb 19, 2008·Expert Review of Anticancer Therapy·Andrew J Kaufman, Harvey I Pass
Aug 4, 2007·The Oncologist·Giovanni Luca CeresoliArmando Santoro
Jan 30, 2008·Nature Clinical Practice. Oncology·Dean A FennellJan van Meerbeeck
Apr 30, 2009·Pathology Oncology Research : POR·Terence C ChuaDavid L Morris
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne S TsaoHedy Lee Kindler
May 5, 2010·Archives of Environmental & Occupational Health·Ugur Gonlugur, Tanseli Efeoglu Gonlugur
Oct 11, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Kyuichi KadotaPrasad S Adusumilli
Jun 23, 2012·Medical Oncology·Emin Tamer ElkiranUNKNOWN Anatolian Society of Medical Oncology Group
Feb 22, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Sheree E Chen, Makala B Pace
Feb 28, 2014·The Journal of International Medical Research·Ozlem AbakayAbdurrahman Abakay
Jul 20, 2014·Thorax·Jenette CreaneyBruce W S Robinson
Jan 23, 2018·Histopathology·Eltjona RrapajRenzo L Boldorini
Jul 31, 2018·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Anna C BibbyGiuseppe Cardillo
Oct 9, 2019·Current Opinion in Supportive and Palliative Care·Andrew C KiddKevin G Blyth
Mar 5, 2002·British Journal of Cancer·J M W van HaarstJ P van Meerbeeck
Apr 9, 2004·American Journal of Respiratory and Critical Care Medicine·Frédéric EbsteinMarc Grégoire
Jul 21, 2006·The Cochrane Database of Systematic Reviews·E ChapmanZ Ortiz
Dec 2, 2004·Expert Opinion on Pharmacotherapy·Anna K NowakBruce W S Robinson
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dean A FennellRobin Rudd
Feb 10, 2009·American Journal of Respiratory and Critical Care Medicine·Bogdan D GrigoriuArnaud Scherpereel
Aug 30, 2012·Acta Oncologica·Kenichi GembaTakumi Kishimoto

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Tüberküloz ve toraks
Deniz Köksal, Sumru Beder
Critical Reviews in Oncology/hematology
H C HoogstedenT van Gelder
Annals of Oncology : Official Journal of the European Society for Medical Oncology
G L CeresoliM A Mirri
The European Respiratory Journal
H SchouwinkF A Zoetmulder
© 2021 Meta ULC. All rights reserved